QCLS supply chain intelligence for Q/C Technologies, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Q/C Technologies, Inc. (QCLS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| LIGHTSOLVER-LTD | LIGHTSOLVER-LTD | 92% | The Company’s relationship with LightSolver provides access to licensed technology that emphasizes the development of LPUs, including the qc-LPU100. |
| LPU-HOLDINGS-LLC | LPU-HOLDINGS-LLC | 92% | the Company agreed to acquire 100% of the membership interests of LPU Holdings LLC from the Sellers |
| PHARMACYTE | PHARMACYTE | 92% | the Company entered into that certain securities purchase agreement with certain accredited investors, including Pharmacyte, pursuant to which it agreed to sell to Pharmacyte an aggregate of 3,000 sh… |
| CHELSEA-VOSS | CHELSEA-VOSS | 90% | Ms. Voss agreed to provide certain consulting services to the Company |
| OCEAN-AVENUE-HOLDINGS-LLC | OCEAN-AVENUE-HOLDINGS-LLC | 90% | Ocean Avenue Holdings agreed to provide certain consulting services to the Company |
| PREMAS-BIOTECH-PVT-LTD | PREMAS-BIOTECH-PVT-LTD | 90% | The Company previously owned, through its former subsidiary Cystron Biotech, LLC (“Cystron”), an exclusive license from Premas Biotech PVT Ltd. (“Premas”) with respect to Premas’ vaccine platform for… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| LIGHTSOLVER-LTD | LIGHTSOLVER-LTD | 85% | laser-based computing system ● our ability to realize value from our legacy pharmaceutical assets, including Isomyosamine (formerly named MYMD-1) and Supera-CBD; ● challenges we may face with maintai… |
| LPU-HOLDINGS-LLC | LPU-HOLDINGS-LLC | 85% | terms of the agreement, the counterparty assigned its rights and interest in certain patents to the Company in exchange for future royalty payments based on a fixed percentage of future revenues, as … |
| MIRA | MIRA | 72% | ivate Placements, the exercise price of the Series F Warrants was reduced to $ 181.60 per share pursuant to the full ratchet anti-dilution provisions contained in the Series F Warrants and the number… |
| MIRA | MIRA | 72% | Reciprocal relationship from MIRA graph: Reciprocal relationship from QCLS graph: ivate Placements, the exercise price of the Series F Warrants was reduced to $ 181.60 per share pursuant to the full … |
| PMCB | PharmaCyte Biotech, Inc. | 72% | Reciprocal relationship from PMCB graph: Reciprocal relationship from QCLS graph: ension or failure. This would not be considered to be within the Company’s control. The estimated fair value of the S… |
| PMCB | PharmaCyte Biotech, Inc. | 72% | ension or failure. This would not be considered to be within the Company’s control. The estimated fair value of the Series F-1 Preferred Stock on the issuance date of approximately $ 9.3 million, was… |
| AKERS-BIOSCIENCES-INC | AKERS-BIOSCIENCES-INC | 62% | ivate Placements, the exercise price of the Series F Warrants was reduced to $ 181.60 per share pursuant to the full ratchet anti-dilution provisions contained in the Series F Warrants and the number… |
| CO-LLC | CO-LLC | 62% | ir market value, as determined using the Black-Scholes option pricing model, of stock options issued to key staff and consultants. 38 Other Income (Expense), net Other income (expense), net consists … |
| GP-NURMENKARI-INC | GP-NURMENKARI-INC | 62% | ir market value, as determined using the Black-Scholes option pricing model, of stock options issued to key staff and consultants. 38 Other Income (Expense), net Other income (expense), net consists … |
| PALLADIUM-CAPITAL-GROUP-LLC | PALLADIUM-CAPITAL-GROUP-LLC | 62% | ir market value, as determined using the Black-Scholes option pricing model, of stock options issued to key staff and consultants. 38 Other Income (Expense), net Other income (expense), net consists … |
| SRQ-PATENT-HOLDINGS | SRQ-PATENT-HOLDINGS | 62% | ivate Placements, the exercise price of the Series F Warrants was reduced to $ 181.60 per share pursuant to the full ratchet anti-dilution provisions contained in the Series F Warrants and the number… |
| TNF-PHARMACEUTICALS-INC | TNF-PHARMACEUTICALS-INC | 62% | reement, the counterparty assigned its rights and interest in certain patents to the Company in exchange for future royalty payments based on a fixed percentage of future revenues, as defined. The ag… |
| Z-LIST-MEDIA-INC | Z-LIST-MEDIA-INC | 62% | ivate Placements, the exercise price of the Series F Warrants was reduced to $ 181.60 per share pursuant to the full ratchet anti-dilution provisions contained in the Series F Warrants and the number… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| QCLS-DEBT-11976 | Warrants outstanding: 61333 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| QCLS-DEBT-11977 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2023-12-31. |
| QCLS-DEBT | Debt stack $307,500 | 90% | Market cache reports total debt of $307,500. |